In a prospective study, S100A8/A9 levels on day 1 of HF in patients after ACS reperfusion therapy accurately classified patients at different HF risk and could serve as a powerful tool for HF risk prediction and treatment guidance (Ma et al., 2025). Here, S100A8 is linked to hydrops fetalis.